1. Sarah Joanna Tabrizi FMedSci FRS is a British neurologist and neuroscientist in the field of neurodegeneration, particularly Huntington's disease.
10 Facts About Sarah Tabrizi
1. 2.
Sarah Tabrizi is a Professor and Joint Head of the Department of Neurodegenerative Diseases at the UCL Institute of Neurology; the founder and Director of the UCL Huntington's Disease Centre; a Principal Investigator at the UK Dementia Research Institute at UCL; and an Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London, where she established the Multidisciplinary Huntington's Disease Clinic.
3.
Sarah Tabrizi obtained a PhD at University College London in 2000.
4.
Sarah Tabrizi undertook an MRC Clinical Training Fellowship PhD studying mitochondrial dysfunction in neurodegeneration with Tony Schapira and Gillian Bates from 1996 to 1999 then obtained a Department of Health National Clinician Scientist Fellowship at the UCL Institute of Neurology in 2002 to work with John Collinge and Charles Weissmann on prion cell biology.
5.
Sarah Tabrizi was promoted to UCL Clinical Senior Lecturer and Honorary Consultant Neurologist in 2003, to Reader in 2007 and Full Professor in 2009.
6.
Sarah Tabrizi gave a keynote presentation at the 2016 Google Zeitgeist Minds conference about her research, and the prospect of gene silencing for neurodegenerative disease.
7.
Sarah Tabrizi was the global lead Clinical Investigator for the first clinical trial of a 'gene silencing' or huntingtin-lowering antisense oligonucleotide drug in Huntington's disease patients.
8.
Sarah Tabrizi is currently working on several different approaches to treat Huntington's disease, including testing novel ASOs targeting MSH3 to slow CAG repeat expansion, allele-selective approaches to target mutant HTT only, and new gene therapy approaches targeting the mutant HD gene.
9.
In 2022, alongside colleagues at the HD Regulatory Science Consortium and CHDI, Sarah Tabrizi developed a novel staging framework, the Huntington's Disease Integrated Staging System, that assesses the progression of disease from birth.
10.
Sarah Tabrizi was the subject of profile articles in The Lancet in 2012 and The Lancet Neurology in 2017.